Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPEL: Bempegaldesleukin + Pembrolizumab in Solid Tumors
NCT03138889Phase 2Terminated
- Sponsor
- Nektar Therapeutics
- Start
- Jun 2017
- Primary completion
- Jul 2022
- Modality
- Cytokines & Interferons
- Countries
- 5
01
Overview
Phase 2, open-label trial of bempegaldesleukin in solid tumor and non-small cell lung cancer (NSCLC) (6 arms), sponsored by Nektar Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 21 days, Treatment-Emergent Adverse Events up to 28 months and 1 more. Started Jun 2017; status: terminated.
02
Drugs
bempegaldesleukin
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03138889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03138889.